Justin Briggs

Justin Briggs is a scientific entrepreneur and investor working at the nexus of biology, chemistry, and engineering. He is a Biologist & Partner at Prime Movers Lab, working to accelerate the portfolio companies and cultivating new breakthrough opportunities. Over the last 15 years, Justin was an operator at nearly a dozen biotech, nanotech, robotics, and software companies with multiple exits and over $100 million in venture backing. Justin also supported venture creation at startup studios such as Deep Science Ventures and Accele Venture Partners. Justin developed novel therapeutics and regenerative medicines in disease areas including oncology, neurology, autoimmune, cardiometabolic, and infectious diseases across ten countries and four continents. Currently, Justin serves on the board of directors for Elevian, Iridia, and Iviva Medical and is a board observer at Morphoceuticals and Dimension Inx.

Prior to joining Prime Movers Lab, Justin developed next-generation biologic medicines, novel pharmaceuticals, diagnostics, and other technologies at companies including Antiverse, Tetherex Pharmaceuticals, Accele BioPharma, Otologic Pharmaceutics, Pamlico BioPharma, Synereca, Jortan Pharma, Altheus Therapeutics, Crescendo Biosciences, and Southwest Nanotechnologies. Justin co-founded TomorrowScale Ventures and startups Chorus Labs, SnapLab Technologies, and Patch Botanics. Justin is knowledgeable across many discovery, development, commercialization, and scaling activities relevant to deep tech and life science companies, has a degree in biomedical sciences from the University of Oklahoma, an MBA with high honors from Oklahoma City University, and is a co-inventor on multiple issued patents.